# Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim

> **NCT04638829** · PHASE4 · COMPLETED · sponsor: **Sobi, Inc.** · enrollment: 60 (actual)

## Conditions studied

- Immune Thrombocytopenia

## Interventions

- **DRUG:** Avatrombopag Oral Tablet

## Key facts

- **NCT ID:** NCT04638829
- **Lead sponsor:** Sobi, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-15
- **Primary completion:** 2024-01-03
- **Final completion:** 2024-01-03
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04638829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04638829, "Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04638829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*